CompanyIXHLNasdaqNorwest Nsw

Incannex Healthcare Ltd

Incannex Healthcare develops combination therapies for obstructive sleep apnea and generalized anxiety disorder.

SEC EDGAR ClinicalTrials.gov incannex.com

10-KSep 25Latest SEC filing

Sep 9Latest story

September 2026

Incannex updates on IHL-42X dosing, new patent, and $70 million cash position

Sep 9Clinical readoutIHL-42X Incannex Healthcare Ltd

August 2026

Incannex doses first patient in Phase 2 DReAMzz trial of IHL-42X

Aug 25Regulatory milestoneIHL-42X Incannex Healthcare Ltd

July 2026

Incannex begins screening patients in Phase 2 sleep apnea trial of IHL-42X

Jul 23Regulatory milestoneIHL-42X Incannex Healthcare Ltd